StreetInsider.com News Articles

IceCure enrolls first patient in breast cancer cryoablation study

Tue, 27 Oct 2026 08:33:38 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) has treated the first patient in its ChoICE post-marketing study, which evaluates the company's ProSense® cryoablation system for the local treatment of low-risk breast cancer.

The treatment was performed at West Cancer Center & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine, a board-certified breast oncology surgeon and Director of the Breast Surgical Oncology Fellowship Program.

The ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites. The study aims to generate real-world data on ProSense® within its FDA-cleared indication. Participating sites are expected to function as both study

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

Tue, 27 Oct 2026 08:33:00 -0400

First patient enrolled and treated at West Cancer Center in Tennessee, USA

CAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

Tue, 27 Oct 2026 08:33:00 -0400

First patient enrolled and treated at West Cancer Center in Tennessee, USA

IceCure enrolls first patients in breast cancer cryoablation study

Tue, 20 Oct 2026 07:56:11 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) announced the enrollment of the first two patients in its post-marketing ChoICE Study, evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer at two U.S. clinical sites.

The first patient was enrolled at West Cancer Center & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine. The second patient was enrolled at Adventist Health Glendale in Glendale, California, a site led by Dr. Dennis Holmes.

The ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and collect real-world data on ProSense® within its FDA-cleared indication. Participating sites

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Tue, 20 Oct 2026 07:55:00 -0400

CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Tue, 20 Oct 2026 07:55:00 -0400

Form 6-K IceCure Medical Ltd. For: Oct 13

Tue, 13 Oct 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20261013/27178016.html

IceCure Medical presents breast cryoablation data at EUSOBI meeting

Tue, 13 Oct 2026 08:05:44 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) announced that its ProSense® breast cancer cryoablation system was featured in scientific presentations, research posters, and physician workshops at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026, held in Maastricht, the Netherlands.

Presentations at the meeting included 12-month clinical data showing objective response rates of 97.5% among 40 patients treated with cryoablation combined with endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone.

Dr. Lucía Graña-López of Spain and Dr. Francesca Pugliese of Italy presented findings related to cryoablation during two scientific sessions. Dr. Pugliese's presentation focused on local tumor control in

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

Tue, 13 Oct 2026 08:05:00 -0400

Scientific presentations, research posters and clinical workshops featured ProSense^®breast cancer cryoablation and highlighted strong physician engagement across Europe

CAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

Tue, 13 Oct 2026 08:05:00 -0400

Scientific presentations, research posters and clinical workshops featured ProSense^®breast cancer cryoablation and highlighted strong physician engagement across Europe

IceCure adds Legacy Health in Portland to breast cancer cryoablation study

Tue, 06 Oct 2026 08:25:45 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) has added Legacy Health in Portland, Oregon, as a U.S. clinical site for its ProSense® ChoICE Study, a post-marketing trial evaluating cryoablation as a treatment for low-risk breast cancer.

Legacy Health's participation will be based at Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center. Nathalie Johnson, M.D., FACS, Senior Medical Director of the Legacy Cancer Institute, will serve as co-primary investigator for the study at the site, alongside co-investigators Marco Aru and Jennifer Garreau.

The ChoICE Study was approved by the U.S. Food and Drug Administration as a post-market study and is designed to enroll approximately

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

Tue, 06 Oct 2026 08:25:00 -0400

CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition of Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

Tue, 06 Oct 2026 08:25:00 -0400

Form 6-K IceCure Medical Ltd. For: Oct 05

Mon, 05 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261005/27148986.html

Form 6-K IceCure Medical Ltd. For: Oct 05

Mon, 05 Oct 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20261005/27145254.html

Form 6-K IceCure Medical Ltd. For: Sep 28

Mon, 28 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27114483.html

Form 6-K IceCure Medical Ltd. For: Sep 10

Thu, 10 Sep 2026 08:51:00 -0400

si-local-file:///var/storage/secattach/20260910/27045828.html

IceCure Medical wins China approval for its ProSense cryoablation system

Thu, 10 Sep 2026 07:59:25 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) announced it has received approval from China's National Medical Products Administration (NMPA) to market its ProSense cryoablation system and associated cryoprobes in China, where it has been classified as a Class III medical device.

The Israel-based company develops liquid-nitrogen-based cryoablation systems that destroy tumors by freezing, targeting breast, kidney, bone, and lung cancers. The ProSense system is already marketed in the U.S., Europe, and parts of Asia.

"We are pleased to receive NMPA approval for ProSense in China, marking an important step in expanding access to IceCure's minimally invasive cryoablation technology," said Eyal Shamir, Chief Executive Officer

IceCure Medical wins China approval for its ProSense cryoablation system

Thu, 10 Sep 2026 07:59:25 -0400

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

Thu, 10 Sep 2026 07:58:00 -0400

CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received approval, as a Class III medical device, from China's National Medical Products Administration ("NMPA") for its ProSense® system and associated cryoprobes.

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

Thu, 10 Sep 2026 07:58:00 -0400

Form 6-K IceCure Medical Ltd. For: Aug 24

Mon, 24 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26964533.html

Form 6-K IceCure Medical Ltd. For: Aug 24

Mon, 24 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26964533.html

IceCure Medical signs Netherlands distribution deal with Scovas Medical

Mon, 24 Aug 2026 07:50:16 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) has entered into an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology applications, according to a company statement.

Under the agreement, Scovas Medical will serve as IceCure's exclusive distributor in the Netherlands for an initial term, with a view toward negotiating a longer-term arrangement. Scovas Medical is an independent medical device distributor based in the Netherlands that serves specialties including interventional radiology and vascular surgery.

The Netherlands is the site of the independent, multicenter randomized THERMAC clinical trial, which evaluated thermal ablation as a treatment

IceCure Medical signs Netherlands distribution deal with Scovas Medical

Mon, 24 Aug 2026 07:50:16 -0400

The Netherlands is the site of the independent, multicenter randomized THERMAC clinical trial, which evaluated thermal ablation as a treatment